AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00112645
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416845
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02572141
Drug: Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
Trial: NCT00767052
Drug: AZD1236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg once daily or 75mg twice daily will be administered in multiple dose part.
Trial: NCT00767052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching to the active in multiple dose part.
Trial: NCT03437304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl dosing volume 200 μl, intranasal administration x 2
Trial: NCT00002804
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00767052
Drug: AZD1236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg single dose will be administered in relative bioavailability part.
Trial: NCT00767052
Drug: AZD1236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg oral suspension single dose will be administered in relative bioavailability part.
Trial: NCT03059238
Drug: Celecoxib 200mg oral capsule
RxNorm normalized name: Celecoxib 200mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03652038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered via inhaler device
Trial: NCT03015675
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20g/day, D1-3, every 2 weeks
Trial: NCT03015675
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Trial: NCT01350973
Drug: Eicosapentaenoic acid-ethyl (EPA-E)
RxNorm normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
Trial: NCT02110368
Drug: AndroGel (testosterone gel) 1.62% Metered-Dose Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03045770
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil was used as first line treatment with AGC.
Trial: NCT03045770
Drug: calcium levofolinate
RxNorm normalized name: calcium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium levofolinate was used as first line treatment with AGC.
Trial: NCT02675491
Drug: DS-6051b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DS-6051b 400 mg or 800 mg daily
Trial: NCT04465487
Drug: REGN6569
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion
Trial: NCT03053700
Drug: Bromonide 0.33% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
Trial: NCT04381962
Drug: Azithromycin Capsule
RxNorm normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg OD PO 14 days
Trial: NCT02482090
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Trial: NCT02408705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
Trial: NCT00022867
Drug: Nondigestible oligosaccharide (NDO)
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01954394
Drug: Lipid-Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT01687998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT01337739
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (.9 normal saline sterile)
Trial: NCT01182675
Drug: Transplant Conditioning with Mobilization Only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
Trial: NCT03464305
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
Trial: NCT03464305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
Trial: NCT03326102
Drug: DHP107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
Trial: NCT03359291
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
Trial: NCT00439634
Drug: AVE1625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00439634
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00124059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/day placebo
Trial: NCT01297179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00025818
Drug: Ophthalmic Emulsion
RxNorm normalized name: Retaine MGD Ophthalmic Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03670966
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03372694
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
Trial: NCT03479996
Drug: Marcaine 0.5 % Injectable Solution
RxNorm normalized name: Marcaine 0.5 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra -operative injection into obturator membrane
Trial: NCT02687542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01786200
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02079220
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Capecitabine~* Oxaliplatin~* Ziv-aflibercept
Trial: NCT02079220
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine Oxaliplatin Ziv-aflibercept
Trial: NCT00309543
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00309543
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03677830
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
Trial: NCT01534312
Drug: Maximal oral 5ASA
RxNorm normalized name: Arthrospira Maxima
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4800 grams/day of Mesalazine (Asacol/Mezavant)
Trial: NCT00705003
Drug: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
Trial: NCT01898806
Drug: Intralesional Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
Trial: NCT02575495
Drug: 7 days course of antibiotic treatment
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
Trial: NCT03947320
Drug: Recombinant Human Coagulation FVIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Trial: NCT03435861
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT01707134
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (s.c, under the skin) as meal time insulin
Trial: NCT01707134
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Trial: NCT02647944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03372694
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
Trial: NCT03969849
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
Trial: NCT03375463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00649324
Drug: Hydrochlorothiazide Tablets (50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, single dose fasting
Trial: NCT03185364
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebos treatment for 12 weeks
Trial: NCT00509561
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01118273
Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Trial: NCT03303378
Drug: melatonin (Helsinn Chemical Co, Biasca, Switzerland)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
Trial: NCT04290663
Drug: Systematic RAI-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
Trial: NCT02367040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
Trial: NCT04278391
Drug: DWJ1421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administered in fasting condition
Trial: NCT04278391
Drug: DWC201903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administered in fasting condition
Trial: NCT02465320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of bioadhesive gel administered by intravaginal insertion
Trial: NCT02714062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po once daily
Trial: NCT02038621
Drug: Oxaliplatin and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
Trial: NCT02953691
Drug: Galacto-Oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
Trial: NCT02161783
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
Trial: NCT03414593
Drug: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
Trial: NCT03303378
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
Trial: NCT04605159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Trial: NCT04365153
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of 5% dextrose infused IV over 2 hours
Trial: NCT01158274
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00393393
Drug: intra-articular injection of Hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03311724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04167553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Trial: NCT02819323
Drug: PEG-ELS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyethylene glycol based bowel preparation
Trial: NCT02819323
Drug: BLI800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI800 bowel preparation
Trial: NCT01118273
Drug: Naproxen Sodium 440 mg (BAYH6689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
Trial: NCT01118273
Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
Trial: NCT01118273
Drug: Naproxen Sodium 220 mg (BAYH6689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
Trial: NCT01118273
Drug: DPH 50mg
RxNorm normalized name: phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
Trial: NCT01118273
Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
Trial: NCT00327379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
Trial: NCT01989312
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04384562
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill is administered only once.
Trial: NCT00229970
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single injection
Trial: NCT03340909
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
Trial: NCT02108171
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Trial: NCT00822900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
Trial: NCT04230330
Drug: IV L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6000 Units/m2 on Days 2 to 8 every 21 days
Trial: NCT03611608
Drug: LY3316531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03611608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02057458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill designed to mimic the sildenafil treatment
Trial: NCT03331861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar dosing regime as active comparator
Trial: NCT03781739
Drug: MANP
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
Trial: NCT00573599
Drug: Imitrex SubQ, saline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitrex SubQ, saline IV
Trial: NCT04605861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.